Dennis L. Sprecher, MD

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Vijay Nambi, MD
Department of Internal Medicine, The Cleveland Clinic

Byron J. Hoogwerf, MD
Director, Internal Medicine Residence Program, Department of Endocrinology, The Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis L. Sprecher, MD, Department of Cardiology, C51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail sprechd@ccf.org

Dr. Sprecher has indicated that he has received grant or research support from the Astra/Zeneca/Merck corporation and is also on its speakers’ bureau. He also serves as a consultant for International Medical Innovations, Inc.

This paper discusses treatments that are not approved by the US Food and Drug Administration for some of the uses under discussion.

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org

Monica Acevedo, MD
Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Dennis L. Sprecher, MD
Head, Section of Preventive Cardiology and Cardiac Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic

Address: Dennis L. Sprecher, MD, Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, C51, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: sprechd@ccf.org